GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Net Change in Cash

ALPMF (Astellas Pharma) Net Change in Cash : $-287 Mil (TTM As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Astellas Pharma's Net Change in Cash for the three months ended in Sep. 2024 was $-69 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $-287 Mil.

Astellas Pharma Net Change in Cash Historical Data

The historical data trend for Astellas Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Net Change in Cash Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.97 71.18 -85.53 455.28 -274.69

Astellas Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,538.73 -555.72 545.37 -207.53 -69.49

Astellas Pharma Net Change in Cash Calculation

Astellas Pharma's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=1151.226+-5645.507+4098.69+120.9
=-275

Astellas Pharma's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=453.37+-114.603+-380.122+-28.135
=-69

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-287 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Net Change in Cash
Comparable Companies
TSE:4151 TSE:4578 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4568 TSE:4519 LLY OCSE:NOVO B JNJ ABBV MRK XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN GILD
Traded in Other Exchanges
ALPMY:USA 4503:Japan YPH:Germany
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Website
http://www.astellas.com
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.